No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
www.vivabiotech.comNo one on the platform currently holds 1873.HK.
No tracked institution reports a position in 1873.HK as of their last filing.
No one on the platform has traded 1873.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.7% | — | — | — | ||
| Rev. Growth % | -12.9% | 19.9% | ||||
| Profit Margin % | 12.7% | 1.4% | 15.4% | |||
| Free Cash Flow Margin % | 5.1% | 1.2% | -7.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.2B | +22.4% | $0.13 | $0.13–$0.13 | — | 1 |
| 2027 | $2.6B | +15.3% | $0.17 | $0.17–$0.17 | — | 1 |
| 2028 | $2.9B | +12.8% | $0.00 | $0.00–$0.00 | — | 0 |
| 2029 | $874M | -70.0% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 1873.HKViva Biotech Holdings | $1.31 | +0.38% | $2.7B | — |
| 1167.HKJacobio Pharmaceuticals Group Co., Ltd. | $5.82 | -2.51% | $4.6B | — |
| 1477.HKOcumension Therapeutics | $5.40 | +0.28% | $4.3B | — |
| 1501.HKShanghai Kindly Medical Instruments Co., Ltd. | $35.00 | -1.02% | $5.7B | — |
| 1541.HKImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
| $3.18 |
| +0.32% |
| $1.3B |
| — |
| 2179.HKJiangsu Recbio Technology Co., Ltd. | $5.00 | +0.00% | $2.7B | — |
| 2509.HKQyuns Therapeutics Co., Ltd. | $16.51 | -0.12% | $3.7B | — |
Source: Financial Modeling Prep · peers by sector/industry